Logan Capital Management Inc. lifted its position in Sanofi SA (NYSE:SNY) by 21.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,377 shares of the company’s stock after purchasing an additional 4,497 shares during the quarter. Logan Capital Management Inc.’s holdings in Sanofi were worth $1,091,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Baldwin Brothers Inc. MA grew its position in Sanofi by 106.7% in the fourth quarter. Baldwin Brothers Inc. MA now owns 11,121 shares of the company’s stock valued at $478,000 after acquiring an additional 5,742 shares during the period. Parametric Portfolio Associates LLC grew its position in Sanofi by 7.0% in the third quarter. Parametric Portfolio Associates LLC now owns 1,558,400 shares of the company’s stock valued at $77,593,000 after acquiring an additional 101,718 shares during the period. Beacon Financial Group grew its position in Sanofi by 12.5% in the fourth quarter. Beacon Financial Group now owns 105,488 shares of the company’s stock valued at $4,536,000 after acquiring an additional 11,761 shares during the period. Epstein & White Financial LLC bought a new stake in Sanofi in the fourth quarter valued at $298,000. Finally, Argent Trust Co grew its position in Sanofi by 32.0% in the third quarter. Argent Trust Co now owns 10,841 shares of the company’s stock valued at $540,000 after acquiring an additional 2,629 shares during the period. Institutional investors and hedge funds own 9.07% of the company’s stock.
Shares of Sanofi SA (NYSE:SNY) opened at $39.85 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59. The company has a market capitalization of $99,624.78, a price-to-earnings ratio of 12.66, a PEG ratio of 2.07 and a beta of 0.85. Sanofi SA has a 1-year low of $38.14 and a 1-year high of $50.65.
Sanofi (NYSE:SNY) last announced its earnings results on Wednesday, February 7th. The company reported $0.62 EPS for the quarter, missing the consensus estimate of $0.69 by ($0.07). The business had revenue of $8.69 billion for the quarter, compared to the consensus estimate of $8.65 billion. Sanofi had a return on equity of 37.09% and a net margin of 23.25%. Sanofi’s revenue for the quarter was down 2.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.25 EPS. research analysts expect that Sanofi SA will post 3.37 EPS for the current fiscal year.
The firm also recently announced an annual dividend, which will be paid on Monday, June 4th. Stockholders of record on Thursday, May 10th will be issued a dividend of $1.8609 per share. This represents a dividend yield of 4.72%. The ex-dividend date of this dividend is Wednesday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.58. Sanofi’s dividend payout ratio is presently 30.14%.
A number of analysts have weighed in on SNY shares. Barclays upgraded Sanofi from an “underweight” rating to an “equal weight” rating in a research report on Wednesday, November 15th. Morgan Stanley cut Sanofi from an “overweight” rating to an “underweight” rating in a research report on Friday, December 1st. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 6th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research report on Thursday, December 14th. Finally, Cowen set a $48.00 price target on Sanofi and gave the company a “hold” rating in a research report on Monday, December 18th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $49.33.
ILLEGAL ACTIVITY WARNING: “Logan Capital Management Inc. Purchases 4,497 Shares of Sanofi SA (SNY)” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/02/23/logan-capital-management-inc-purchases-4497-shares-of-sanofi-sa-sny.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.